Last updated: 2026-09-04 21:44:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Beam Therapeutics Inc. (BEAM) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $29.65, with a market capitalization of $3.03B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $17.74 to $38.26. This page covers its latest market performance, valuation, price trends and company information.
$3.03B | |
$28.91 | |
$138.52 | |
$13.00 | |
$29.46 | |
972.39K | |
-- | |
-- | |
$38.26 | |
$17.74 | |
-- | |
-- |
Beam Therapeutics Inc. (BEAM) is trading at $30.16 in after-hours trading as of 2026-09-04 21:43:00, up 2.38% ($0.70) from the regular-session close of $29.46.
After-hours trading shows how investors are pricing BEAM after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Beam Therapeutics Inc. (BEAM) moved from $28.82 to $29.65, representing a gain of 2.87% ($0.83).
The stock traded between $28.91 and $29.92 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 1.22 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 58.0%
BEAM is currently trading at $29.65, placing it 58.0% of the way from its 52-week low of $17.74 to its 52-week high of $38.26. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 540 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Beam Therapeutics Inc. (BEAM) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.